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Abstract
Although vaccination significantly reduces influenza severity, seasonal human influenza
epidemics still cause more than 250,000 deaths annually. Vaccine efficacy is limited in high-risk
populations such as infants, the elderly and immunosuppressed individuals. In the event of an
influenza pandemic (such as the 2009 H1N1 pandemic), a significant delay in vaccine availability
represents a significant public health concern, particularly in high-risk groups. The increasing
emergence of strains resistant to the two major anti-influenza drugs, adamantanes and
neuraminidase inhibitors, and the continuous circulation of avian influenza viruses with pandemic
potential in poultry, strongly calls for alternative prophylactic and treatment options. In this
review, we focus on passive virus neutralization strategies for the prevention and control of
influenza type A viruses.
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Influenza type A viruses belong to the family Orthomyxoviridae and contain a segmented,
negative-sense ssRNA genome [1]. Type A influenza viruses are further divided into
subtypes based on the antigenic characteristics of the two major surface glycoproteins,
hemagglutinin (HA) and neuraminidase (NA). Sixteen HA subtypes and nine NA subtypes
have been described so far. The lack of proofreading activity of the influenza type A virus's
polymerase and the host's immune pressure lead to rapid mutations, resulting in antigenic
drift and evasion of the host's immune surveillance. The segmented nature of the virus
genome promotes reassortment, which can lead to novel strains with pandemic potential [2].
Humans have experienced four major influenza pandemics in the last 100 years: the Spanish
flu of 1918, the Asian flu of 1957 (H2N2), the Hong Kong flu of 1968 (H3N2) and the
North American flu of 2009 (H1N1) [3,4]. The rates of illness and death of these influenza
pandemics were variable. The 1918 Spanish flu is reported to have claimed the lives of 50
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million people, whereas the more recent 2009 H1N1 flu was characterized as an atypical
mild pandemic and associated with approximately 14,000 deaths [5–8]. Global seasonal
influenza can cause up to 1 billion infections annually, of which 4 million are severe and
lead to more than 250,000 deaths [9]. More importantly, the continuous circulation and
evolution of highly pathogenic avian H5N1 influenza viruses in poultry and other avian
influenza viruses in vast geographic areas of Asia, the Middle East and parts of Africa, with
the ability to cause severe disease in humans, poses a major pandemic threat [10–12].
Influenza vaccination significantly reduces the morbidity and mortality of seasonal
influenza; however, its efficacy is limited in high-risk populations such as infants, the
elderly and the immuno suppressed [13,14]. The lack of pre-existing immunity to pandemic/
zoonotic strains, or even epidemic strains, can lead to a severe influenza disease that
requires immediate antiviral treatment. Currently, two kinds of anti-influenza drugs are
licensed and commercially available in the USA: adamantanes inhibitors and NA inhibitors
(NAIs). Adamantanes (e.g., amantadine and rimantidine) block the proton-pump activity of
the matrix protein 2 (M2) transmembrane viral protein, which leads to the inhibition of
structural changes on the viral HA, the consequent failure in the fusion of the viral and
endosomal membranes and the sequestration of the virus replication machinery in the
endosome. The NAIs, oseltamivir (Tamiflu®, Roche, San Francisco, CA, USA) and
zanamivir (Relenza®, GSK, Philadelphia, PA, USA), act mostly during virus budding, by
strongly binding the NA catalytic site, inhibiting its activity and causing virus aggregation,
which in turn results in less infectious particles.
Unfortunately, these drugs have a very narrow window of opportunity to be effective and
must be administered within the first 48 h of onset of symptoms [15,16]. In addition, a major
challenge for current antiviral drugs is that drug-resistant variants can emerge naturally or
through selective pressure during treatment [15,16]. Single point mutations at either amino
acids (aa) 26, 27, 30, 31 or 34 in M2 can confer resistance to adamantanes [9]. All 2009
pandemic H1N1 viruses show resistance to adamantanes owing to the presence of a S31N
mutation in M2 [17]. During the 2007–2008 season, H1N1 viruses rapidly developed
resistance to oseltamivir, from 12.3 to 98.5% [17], and NAI-resistant strains were also
observed in the 2009 pandemic virus. The oseltamivir-resistant 2009 pandemic virus
carrying the H275Y substitution was first detected in Japan, Denmark and Hong Kong
during May–June 2009, and has since been identified sporadically around the world [17–
21]. Oseltamivir-resistant H5N1 viruses with NA mutations (H274Y and N294S) have also
been identified in infected patients during or after treatment [16]. Therefore, adequate
antiviral alternatives are needed to minimize the effects and the spread of the disease. Since
antibodies play a crucial role in protection against influenza infection [22], passive
immunotherapy is a plausible antiviral strategy for the control of influenza disease. In this
short review, we focus on passive virus neutralization strategies for the prevention and
control of influenza, particularly type A influenza.
Epitopes & mechanisms for influenza virus neutralization
Type A influenza viruses encode at least 11 polypeptides from eight RNA segments (Figure
1). Segment 1 (2341 nucleotides [nt]) encodes the polymerase subunit PB2 (759 aa),
segment 2 (2341 nt) encodes the polymerase subunit polymerase basic protein (PB1) (757
aa) and, from an alternative start site, PB1-F2 (~87–101 aa, although most human strains
encode truncated PB1-F2 genes of less than 50 aa). Segment 3 (2233 nt) encodes the
polymerase subunit (PA; 716 aa), segment 4 (~1766 nt, although the length varies depending
on the subtype) encodes HA (~570 aa), segment 5 (1565 nt) the nucleoprotein (NP; ~504 aa)
and segment 6 (~1467 nt) NA (~473 aa). Segments 7 (1023 nt) and 8 (890 nt) each encode
for two polypeptides via alternative splicing: matrix protein (M); 252 aa) and M2 (97 aa),
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and nonstructural protein 1 (NS1; ~230 aa) and nuclear export protein (NEP; 121 aa),
respectively.
Epitopes recognized by the humoral and T-cell arms of the immune system are found in all
of the influenza proteins; however, those that are the most important in terms of neutralizing
activity, such as blocking the infection and limiting virus replication, are found on the HA
and NA surface glycoproteins, and, to a lesser extent, on the M2 transmembrane protein
(Figure 1) [23,24]. HA is present as a homotrimer and is the major virus target antigen
recognized by neutralizing antibodies [25]. The HA monomer is first synthesized as a
precursor molecule, HA0, then is post-translationally cleaved by trypsin-like proteases
found in the lumen of the respiratory or intestinal tracts (or intracellular subtilisin-like
proteases in the case of highly pathogenic strains of the H5 and H7 subtypes). The
proteolytic cleavage generates two subunits, HA1 and HA2, which are subsequently linked
by a disulfide bridge [25]. Each monomer is then maintained in the homotrimer by HA2
subunits via a noncovalently bound coiled structure. The HA1 subunit forms the globular
head of the HA protein and contains the receptor-binding site and the dominant antigenic
sites that have been mapped using monoclonal antibodies [25]. For the H3 subtype, HA1
contains seven antigenic sites labeled A, B1, B2, C1, C2, D and E, whereas antigenic sites in
the H1 subtype are designated Sa, Sb, Ca1, Ca2 and Cb [26,27]. The antigenic sites A, B1,
B2, C1 and C2 cover aa positions 121–146, 155–163, 186–197, 50–57 and 275–279,
respectively. Site D is located spanning positions 207–219 and site E spans positions 62–83
(Figure 2) [26]. Antibodies against HA1 can efficiently block virus attachment to target
cells and/or interfere with virus–host receptor interactions to neutralize the virus (Figure
3A) [28–30]. The inherent variability of the HA molecule permits constant antigenic drift
and escape from the neutralizing antibody response [24,31]. This is also the reason for the
reformulation of human influenza vaccines and for the need of annual revaccination [32]. In
order to confer protection, the HA antigen in the vaccine must match the circulating strains
in the population.
HA2 forms a stem-like structure that mediates the anchorage of HA to the virus membrane
[24,31]. In addition, HA2 contains the fusion peptide that is released by proteolytic cleavage
of HA0 precursor molecule and exposed during its structural changes under low pH
conditions [25,33]. The outcome of the fusion process is the release of the viral
ribonucleoprotein (vRNP) complexes into the infected cell. By contrast to the HA1 subunit,
the HA2 is more conserved within and among different subtypes and is less prone to
antigenic drift. HA2 contains at least four antigenic sites designated antigenic sites I, II, III
and IV. Based on the H3 HA structure, antigenic site I covers aa positions 346–383,
antigenic sites II and IV locate in the same stretch 470–520 and antigenic site III covers
positions 383–457 (Figure 2) [34]. Monoclonal antibodies against HA2 generally show
broad cross-reactivity among different influenza subtypes and some of these have been
shown to provide efficient cross-protection against multiple subtypes in lethal mouse models
[35–48]. The cross-protective action of these antibodies is mainly mediated by inhibiting the
fusion of viral and endosomal membranes and thus, blocking the release of vRNP and virus
replication (Figure 3B) [34,37,38,41,49]. Although the epitopes of HA2 are less exposed,
they do induce a discernible antibody response [50,51]. Recently, Wrammert et al. reported
that 10% of human monoclonal antibodies recovered from plasma-blast cells from pandemic
2009 H1N1-infected patients could bind to a conserved epitope on the HA2 [36]. More
recently, Ekiert et al. isolated a human neutralizing monoclonal antibody (mAb; CR8020)
with broad activity against most group 2 influenza viruses [52]. At the same time, Corti et
al. reported a human neutralizing mAb (FI6) that can react with all 16 HA subtypes [53].
The two monoclonal antibodies target highly conserved epitopes located in the fusion
peptide of the HA2 portion. FI6 showed neutralizing activity in vitro and was also effective
in vivo in protecting mice and ferrets against both group 1 and group 2 influenza viruses
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[53]. Therefore, the HA2 epitopes are sought out as potential targets for h eterosubtypic
universal vaccines [31,34,54].
NA is the second-most abundant influenza glyco protein. NA is a type 2 glycoprotein and is
present in a mushroom-like homotetrameric structure. The activity of NA is important for
the release of discrete virus particles during budding from infected cells [24]. NA activity is
also associated with exposure of pneumococcal receptors, increasing the possibility of post-
influenza-secondary bacterial pneumonia [55–57]. Thus, although NA appears to play no
role in viral attachment and/or penetration to the host cell, increasing evidence suggests that
antibodies against NA can prevent virus release, resulting in reduced virus production and
decreasing the severity induced by s econdary pneumococcal infection (Figure 3C) [58–61].
M2, a single type 3 viral membrane protein, is present as a homotetramer [62]. The proton
channel activity of M2 is essential for release of the viral genome into the cell [15]. In M2,
the extracellular N-terminal domain (eM2; a 23 aa peptide) is highly conserved among
influenza A strains and, therefore, represents an attractive target for generating universal
vaccines [54]. The eM2 is poorly immunogenic and antibodies are hardly detectable in
humans after natural infection [63]. However, several studies have shown that antibodies
against eM2 can provide protection against lethal influenza challenge in animal models [64–
69], and a recent study found that more than 15% (23 out of 140) of individuals sampled had
detectable antibodies against eM2 [70]. The same study also showed the rescue of a human
monoclonal eM2 antibody from B cells, which elicited protection against lethal challenges
with either H5N1 or H1N1 in the mouse model [70]. Although eM2 does not naturally
induce a strong immune response, studies with antibodies against eM2 have shown the
occurrence of escape mutants when selective pressure is applied [71]. Since eM2 antibodies
do not block virus attachment to cells, their mechanism of action likely involves the
constraining of proton transport activity and thus preventing structural changes on the HA
needed for fusion and uncoating of vRNPs (Figure 3B), and/or antibody dependent cell-
mediated cytotoxicity or complement-dependent cytotoxicity effects [64,72].
Sources of neutralizing antibodies for passive immunotherapy
The plasma from convalescent individuals, as a source of neutralizing antibodies for use in
passive immunotherapy, has been used for the treatment for many virus infections, including
measles virus, Ebola virus, Junín virus, CMV, respiratory syncytial virus (RSV), smallpox
virus, hepatitis A and B viruses and rabies virus [73–81]. Passive immunotherapy using
plasma has a long history of effectiveness and safety. So far, seven human polyclonal
immunoglobulins have been approved by the US FDA for passive immunotherapy of virus
infections (Table 1) [82–88]. In the case of influenza virus, convalescent plasma was
reported to be beneficial in reducing clinical mortality during the 1918 Spanish influenza
pandemic [89], a time in which neither antivirals, nor antibiotics were available. H5N1-
infected patients treated with convalescent H5N1 plasma showed a significant reduction in
virus load and eventually recovered [90]. Treatment of severe H1N1 2009 infections with a
single dose of convalescent plasma could significantly reduce respiratory virus load, serum
cytokine responses and mortality [91]. These reports highlight that plasma from
convalescent influenza patients can be used as an effective therapeutic alternative,
particularly during severe influenza infections, perhaps in combination with other antivirals
or instead of other antivirals, if these are not available.
Although human convalescent plasma reflects the full spectrum of the natural immune
response, its production is highly dependent on blood donors, and considerable variations
are expected between batches in terms of specificity, quantity and suitability [92]. The mAb
technique introduced initially by Kohler and Milstein provided an answer to the challenges
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set by the use of convalescent plasma [93]. Monoclonal antibodies not only show high
antigen specificity, but also can be produced in unlimited quantities [93]. More recently, the
generation of either humanized or human monoclonal antibodies has led to an explosion in
approaches using passive immunotherapy. A ‘humanized’ IgG mAb against RSV is
commercially available for high-risk infants for the prevention and treatment of RSV
infections [94]. In the case of influenza, neutralizing mAbs against highly pathogenic H5N1
and broadly neutralizing, subtype-independent mAbs have received considerable attention
[36,39,70,95–100]. Several studies show that mAbs against the influenza virus are effective
in passive protection in animal models [39,95–100]. More recently, two independent studies
utilizing B cells from human blood donors in combination with antibody engineering
techniques led to the identification of broadly neutralizing mAbs against epitopes in the eM2
and HA2 subunit, respectively [36,70]. In these studies, the influenza-specific antibody-
secreting cells were first isolated and/or enriched from human peripheral blood mononuclear
cells, and then the IgG variable regions (VH and VL) were amplified and cloned into a
human IgG1 expression vector in order to generate human monoclonal antibodies.
Furthermore, mice treated with these antibodies were protected against lethal challenge with
highly divergent influenza subtypes, highlighting their potential for clinical passive
immunotherapy [36,70]. Although the ‘humanized’ IgG mAb against RSV is the only
commercial mAb approved by the FDA for prevention of a viral disease, the FDA has
approved more than 30 mAbs for therapeutic use for other noninfectious diseases. Of note,
mAbs against HCV, dengue virus and influenza virus are in the process of seeking approval
for commercialization (Table 1) [70,101–103,201].
In addition to human convalescent plasma and mAbs against influenza, chicken IgY, which
can be produced in high concentrations in egg yolk and because of its high stability, is
another excellent potential resource for passive immunotherapy. Studies in animals and
humans have demonstrated the passive immunoprotective effects of IgY against different
pathogens [104–108]. In humans, oral administration of IgY specific to Helicobacter pylori
could reduce Helicobacter infections, and antigen-specific IgY was also shown to be
effective against Pseudomonas aeruginosa infections in cystic fibrosis patients [107,108].
The effects of IgY are not restricted to pathogens of the GI tract or to the oral route for
entry. Treatment of chickens with anti-H5N1-specific IgY antibodies, produced in ostrich
eggs, resulted in a dramatic decrease in mortality after lethal H5N1 challenge [109]. Mice
treated via the intranasal route with anti-H5N1 or anti-H1N1 chicken IgY antibodies were
protected against lethal challenge with H5N1 or H1N1 viruses, respectively [110]. In this
same study, it was shown that IgY treatment could induce anti-IgY antibodies in mice;
however, these antibodies did not interfere with the neutralizing activity of the chicken IgY
[110]. It is important to note that IgY antibodies cannot trigger the human complement
system or bind to the human Fc receptor and, therefore, it is unlikely that they would
mediate antibody-dependent enhancement of disease or complement-mediated inflammation
[111]. These studies highlight influenza virus-specific IgY, present in eggs as a natural food
source for humans, as an enormous source for influenza-passive immunotherapy.
Delivery strategies for passive neutralizing influenza antibodies
Passive neutralizing antibodies can be administered via multiple routes, including the oral,
intranasal, intraperitoneal, intramuscular and intravenous routes. In humans, passive
immunotherapy with convalescent plasma is generally given via intramuscular and
intravenous routes. In mice, however, the protective effects of either mouse- or human-
derived mAbs have relied mostly on intraperitoneal administration before or after challenge
with the pathogen of choice [39,95–100]. In the case of influenza, an obligatory respiratory
virus in humans, administration via the respiratory route could be considered viable, as
severely ill patients may be assisted by mechanical ventilation devices, which can be
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adjusted to administer drugs [112,113]. In mice, mAbs against H5N1 and the 2009
pandemic H1N1 virus were administered intranasally and shown to be effective in challenge
studies. A single intranasal dose of anti-H5 IgA mAb either at 24, 48 or 72 h prior to H5N1
sublethal challenge resulted in no bodyweight losses, no clinical signs of disease and
significantly decreased virus load in the lungs compared with mock treated controls.
Administration either at 24, 48 or 72 h post-H5N1 sublethal challenge provided 100, 80 and
60% protection, respectively [99]. It was also shown that a single intranasal dose of anti-
H1N1 (2009 pandemic) IgG-neutralizing mAb could provide protection against lethal
influenza challenge, even when administrated 72 h prior to or postchallenge [114]. These
studies show that anti-influenza neutralizing activity could be maintained for at least 72 h in
the respiratory tract, suggesting that respiratory administration of mAbs could be an
alternative route for the treatment of influenza. Of note, the anti-H5N1 chicken IgY
described above only provided protection if it was given via the intranasal route in mice
[110]. No protective effect of such IgY was observed when administered via the oral or
intraperitoneal routes, even though the chicken IgY could be detected in the sera of treated
mice [110]. It remains to be determined whether administration of anti-H5N1 IgY would
provide significant protection in chicken.
Conclusion & future perspective
Passive immunization is an immediate preventative and therapeutic strategy for infectious
diseases and has been accepted in the treatment of many virus infections such as RSV,
smallpox virus, the hepatitis A and B viruses and rabies virus. This strategy would be
beneficial for high-risk populations, such as immunosuppressed individuals, individuals with
poor vaccine coverage and/or when other antiviral options were either not available or have
failed. A Phase I study of one human mAb (TCN-032) against M2 is being evaluated for
passive immunization against influenza viruses [70,201].
Perhaps the major challenge in developing a suitable immunotherapy approach against
influenza is the inherent ability of the virus to constantly evolve, thus readily evading the
immune system. In this regard, the identification of highly cross-reactive human mAb
against the eM2 and HA2 subunit constitute major steps towards a universal immunotherapy
approach. Broad human neutralizing mAbs, such as TCN-032, CR6261, CR8020 and FI6,
show great thera peutic potential against influenza viruses [52,53,70,201]. If these mAbs
become a viable alternative for prevention and treatment of influenza, it remains to be seen
whether escape mutants can readily emerge. Even though NAIs were designed in silico,
were shown to have excellent antiviral activity in vitro and deemed unlikely to promote the
emergence of resistant strains, nature has shown otherwise. NAI-resistant strains have
emerged for seasonal H1N1 and H3N2 strains, and readily emerged during the 2009 H1N1
pandemic. Thus, it is plausible that, once an immune reagent is used for the prevention or
treatment of influenza, the virus finds a way to resist such pressure. This is the case in RSV,
a human paramyxovirus that shows much less antigenic variation than influenza viruses, but
for which resistant strains emerged during treatment with the commercially available
humanized IgG1 mAb palivizumab [115]. An alternative to the limitation of using a single
mAb would be to use a cocktail of neutralizing mAbs with specificity for various epitopes.
Such a cocktail of mAbs has been used for the treatment of rabies [116]. A clinical Phase II
study demonstrated the cocktail was safe and as effective as the human rabies
immunoglobulin [116].
Since rapid and efficient transmission is a characteristic of influenza viruses, particularly of
pandemic strains, blocking transmission could certainly curtail the disease burden of these
viruses. In this regard, the work by Tsukamoto et al. [117] is worth noting, since it was
observed that air filters impregnated with ostrich IgY specific to H5N1 prevented the
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transmission of the H5N1 virus to chickens [117], suggesting that specific influenza-
neutralizing antibodies could be applied to facial masks or air-conditioning filters to prevent
the population from influenza infections. Thus, immunological approaches to prevent
influenza infections are not restricted to the administration of antibodies to individual
subjects. Instead, alternative approaches, like those described by Tsukamoto et al. [117]
could effectively prevent the spread of the disease.
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■ A vaccine's efficacy is limited in high-risk populations such as infants, the elderly
and immunosuppressed individuals. In the event of an influenza pandemic, a
significant delay in vaccine availability represents a significant public health
concern. In addition to these, the increasing emergence of strains resistant to the two
kinds of anti-influenza drugs licensed by the US FDA strongly calls for alternative
prophylactic and treatment options.
■ Since antibodies play a crucial role in protection against influenza infection,
passive immunotherapy is a plausible antiviral strategy for the control of influenza
disease.
Epitopes & mechanisms for influenza virus neutralization
■ Three surface proteins, hemagglutinin (HA), neuraminidase (NA) and matrix
protein 2 (M2), are major targets to induce neutralizing antibodies against the
influenza virus.
■ Antibodies against HA1 can efficiently block virus attachment and/or interfere
with virus–host receptor interactions in order to neutralize the virus. Antibodies
against HA2 can inhibit the fusion of viral and endosomal membranes, and thus
block the release of viral ribonucleoproteins and reduce viral replication.
■ Antibodies against NA can prevent viral release, resulting in reduced viral
production and decreasing the severity induced by secondary pneumococcal
infection. Antibodies against M2 can constrain proton transport and the structural
change that occurs to HA during the fusion, and thus block the viral
ribonucleoprotein uncoating.
■ As there are highly conserved epitopes in HA2 and M2, antibodies against HA2
and M2 generally show broadly neutralizing activity against different influenza virus
subtypes and are considered as potential universal antibodies against influenza.
Sources of neutralizing antibodies for passive immunotherapy
■ Human convalescent plasma was reported to be beneficial in reducing clinical
mortality during the 1918 Spanish influenza pandemic, in H5N1 infected patients
and in severe H1N1 2009 infections.
■ The generation of monoclonal antibodies (mAbs), either humanized or human
mAbs, has led to an explosion in approaches using passive immunotherapy.
■ Utilizing influenza-specific antibody-secreting cells isolated and/or enriched from
human peripheral blood mononuclear cells in combination with antibody engineering
techniques has led to the identification of broadly neutralizing mAbs against epitopes
in the M2 extracellular N-terminal domain (eM2) and HA2 subunit.
■ Lots of mAbs against influenza viruses have been reported to be efficiently
protective in animal models such as the mouse and ferret. A Phase I study of one
human mAb (TCN-032) against M2 is being evaluated for passive immunization
against influenza virus.
■ Chicken IgY, produced in high concentrations in egg yolk and with high stability,
is another excellent potential resource for influenza passive immunotherapy.
Chicken IgY against specific influenza virus subtype has been reported to be
protective in the mouse and chicken models.
Delivery strategies for passive neutralizing influenza antibodies
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■ Passive neutralizing antibodies can be administrated via multiple routes, including
the oral, intranasal, intraperitoneal, intramuscular and intravenous routes.
■ In humans, passive immunotherapy with convalescent plasma is generally given
via intramuscular and intravenous routes. In mice, the protective effects of mAbs
have relied mostly on intraperitoneal administration before or after challenge.
■ In the case of influenza, an obligatory respiratory virus in humans, administration
via the respiratory route could be considered viable, just like the intranasal delivery
of live attenuated influenza seasonal vaccines.
■ Animal models (mouse and chicken) have shown that intranasal delivery of mAbs
or chicken IgY could provide efficient protection, even when antibodies are
administrated 72 h prior to or postchallenge.
Conclusion & future perspective
■ Influenza-passive immunotherapy would be beneficial for high-risk populations
such as immunosuppressed individuals or individuals with poor vaccine coverage
and/or when other antiviral options were either not available or have failed.
■ Perhaps the major challenge in developing a suitable immunotherapy approach
against influenza is the inherent ability of the virus to constantly evolve, thus readily
evading the immune system. The identification of highly cross-reactive human mAbs
by antibody engineering techniques constitutes a major step towards a universal
immunotherapy approach.
■ A cocktail of broad human neutralizing mAbs against the eM2 and HA2 subunit,
such as TCN-032, CR6261, CR8020 and FI6, shows great therapeutic potential
against influenza viruses.
■ Since rapid and efficient transmission is a characteristic of influenza viruses,
particularly of pandemic strains, blocking transmission could certainly curtail the
disease burden of these viruses. Specific influenza neutralizing antibodies could be
applied to facial masks or air-conditioning filters to prevent the population from
influenza infections.
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Figure 1. Molecular structure of influenza A viruses
The virus contains a lipid bilayer derived from the host plasma membrane. Two surface
glycoproteins, HA and NA, are the major antigenic determinants of the virus. The virus
surface also carries a few copies of an ion channel proton pump (M2). Eight vRNA
segments, each one of them associated to three polymerase subunits (PB2, PB1 and PA) and
several copies of NP [6], are located inside the virion, protected by a protein mesh provided
by the M. In addition, the virus carries a few copies of the virus-encoded NEP. In infected
cells, the virus expresses NS1 and some influenza strains express PB1-F2, derived from the
second open reading frame of segment 2.
HA: Hemagglutinin; M: Matrix protein; M2: Matrix protein 2; NA: Neuraminidase; NEP:
Nuclear export protein; NP: Nucleoprotein; PA: Polymerase acidic protein; PB: Polymerase
basic protein; vRNA: Viral RNA.
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Figure 2. Structure of hemagglutinin and antigenic sites
The illustration was prepared by using MacPymol© (DeLano Scientific, CA, USA) based on
the structure of H3 hemagglutinin (Protein Data Bank accession code 1HGE). The aa
forming antigenic site A were marked in red. Antigenic site B1, B2, C1, C2, D and E were
marked in blue, forest green, purple, green, pink and yellow, respectively. Antigenic site I in
HA2 was marked in magenta, sites II and IV were marked in orange and site III was labeled
in cyan.
aa: Amino acid.
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Figure 3. The action of influenza virus-neutralizing antibodies
(A) Antibodies against HA1 can efficiently block virus attachment to target cells and/or
interfere with virus–host receptor interactions to neutralize the virus. (B) Antibodies against
HA2 can inhibit the fusion of viral and endosomal membranes and thus, block the release of
viral ribonucleoproteins and reduce virus replication. (C) Antibodies against NA can prevent
virus release, resulting in reduced virus production and decreasing the severity induced by
secondary pneumococcal infection. (D) Antibodies against M2 can constrain proton
transport, HA structure change during the fusion and thus, block the viral ribonucleoprotein
uncoating. Antibodies such as IgG and IgA could be internalized into the cell through FcRn
and pIgR, respectively, thus resulting in effective antiviral activity [118,119]. The site of
action of these antibodies is not exactly known, although it could be associated the
endoplasmic reticulum and/or trans-golgi apparatus.
HA: Hemagglutinin; NA: Neuraminidase.
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Table 1
Therapeutic polyclonal and monoclonal antibodies against viruses.
Target Name Source Major indication Ref.
RSV Respigam† Human polyclonal immune globulin Prophylactic treatment of RSV in infants
[82]






Human polyclonal immune globulin Prophylaxis against chickenpox [83]
Vaccinia virus VIG† Human polyclonal immune globulin Treatment of smallpox vaccine side effects
[84]







Human polyclonal immune globulin Postexposure prevention of rabies [86]




Human polyclonal immune globulin Postexposure prevention of hepatitis A [88]




Mouse monoclonal antibodies Therapeutic activity against DENV [102,103]
Influenza A virus TCN-032‡ Human monoclonal antibodies Treatment of pandemic and severe seasonalinfluenza
[70,201]
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